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Aims Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial ﬁbrillation (AF). In patients
with recently decompensated congestive heart failure (CHF) and depressed LV function, the drug was associated with
excess mortality compared with a placebo group. The present study aimed to analyse in detail the effects of drone-
darone on mortality and morbidity in AF patients CHF.
Methods
and results
We performed a post hoc analysis of ATHENA, a large placebo-controlled outcome trial in 4628 patients with
paroxysmal or persistent AF, to evaluate the relationship between clinical outcomes and dronedarone therapy in
patients with stable CHF. The primary outcome was time to ﬁrst cardiovascular (CV) hospitalization or death.
There were 209 patients with NYHA class II/III CHF and a left ventricular ejection fraction ≤0.40 at baseline (114
placebo, 95 dronedarone patients). A primary outcome event occurred in 59/114 placebo patients compared with
42/95 dronedarone patients [hazard ratio (HR) 0.78, 95% CI ¼ 0.52–1.16]. Twenty of 114 placebo patients
and 12/95 dronedarone patients died during the study (HR 0.71, 95% CI ¼ 0.34–1.44). Fifty-four placebo and 42
dronedarone patients were hospitalized for an intermittent episode of NYHA class IV CHF (HR ¼ 0.78, 95%
CI ¼ 0.52–1.17).
Conclusion In this post-hoc analysis of ATHENA patients with AF and stable CHF, dronedarone did not increase mortality
and showed a reduction of CV hospitalization or death similar to the overall population. However, in the light of
the ANtiarrhythmic trial with DROnedarone in Moderate to severe CHF Evaluating morbidity DecreAse study,
dronedarone should be contraindicated in patients with NYHA class IV or unstable NYHA classes II and III CHF.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Dronedarone is a new multichannel blocking antiarrhythmic drug
for the treatment of patients with atrial ﬁbrillation (AF). Two
large randomized placebo-controlled trials have demonstrated
the rhythm-controlling efﬁcacy of the compound.
1 In addition, dro-
nedarone has been shown to have rate-controlling properties in
patients with permanent AF.
2 In ATHENA [A placebo-controlled,
double-blind, parallel arm trial to assess the efﬁcacy of
dronedarone 400 mg bid for the prevention of cardiovascular
(CV) hospitalization or death from any cause in patients with
AF/atrial ﬂutter (AFL)], a large outcome trial in 4628 patients, dro-
nedarone reduced major clinical outcomes in patients with AF
including CV hospitalizations, CV mortality, and stroke.
3
However, the ANDROMEDA [ANtiarrhythmic trial with DROne-
darone in Moderate to severe congestive heart failure (CHF) Eval-
uating morbidity DecreAse] study in patients with recently
decompensated heart failure and depressed left ventricular
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dronedarone arm relative to the placebo group.
4 The reasons
for the observed excess mortality have not been fully elucidated.
In order to investigate in more detail the effects of dronedarone
in AF patients with stable CHF, we performed an exploratory
analysis of ATHENA to evaluate the relationship between clinical
outcomes and dronedarone therapy in this important subpopu-
lation of patients.
Methods
The design and the primary results of the ATHENA trial have been
previously published.
3,5 In short, patients with paroxysmal or persistent
AF and at least one additional risk factor for CV events including age
≥75 years or ,75 years with one or more of the following risk
factors: hypertension, diabetes mellitus, prior stroke or TIA, left
atrial enlargement (≥50 mmHg), or depressed left ventricular ejection
fraction (LVEF) (≤0.40) were eligible. They were randomized to
receive dronedarone 400 mg bid or matching placebo. Main exclusion
criteria were unstable haemodynamic condition, such as CHF of
NYHA functional class IV within 4 weeks, and presence of permanent
AF. The follow-up visit schedule included clinical evaluations at days 7
and 14 and at months 1, 3, 6, 9, 12 and every 3 months thereafter. In
the case of clinical deterioration, patients were seen as indicated clini-
cally. At each visit, a physical examination was performed and a 12-lead
electrocardiogram (ECG) was recorded at each visit up to 6 months
and every 6 months thereafter.
The primary outcome measure was time to ﬁrst CV hospitaliz-
ation or death [hazard ratio (HR) ¼ 0.76, 95% CI ¼ 0.69–0.84,
P , 0.001].
3 Pre-speciﬁed secondary outcome measures were
total mortality (HR ¼ 0.84, 95% CI ¼ 0.66–1.08, P ¼ 0.18), CV
mortality (HR ¼ 0.71, 95% CI ¼ 0.51–0.98, P ¼ 0.03), and CV hos-
pitalization (HR ¼ 0.74, 95% CI ¼ 0.67–0.82, P , 0.001).
3 Deaths
were categorized by a blinded Adjudication Committee into four
categories: cardiac arrhythmic; cardiac non-arrhythmic; vascular
non-cardiac; and non-vascular. Information on the occurrence of
new or worsened CHF was gathered from hospitalization and
death reports which included speciﬁc information on the occur-
rence of CHF.
Analyses were performed on the intention-to-treat population. The
time to event was estimated according to the non-parametric Kaplan–
Meier method and compared by a two-sided log-rank’s asymptotic
test. Hazard ratio was calculated using Cox’s proportional hazard
model with treatment group as covariate. Interactions between
several subgroups were tested using a likelihood ratio test. All
P-values were two-tailed and threshold used for signiﬁcance was
0.05. Statistical analyses were done using SAS version 8.2 on UNIX
environment.
Results
A total of 4628 patients were enrolled in ATHENA with 2301
assigned to dronedarone and 2327 to placebo. Overall, there
was no signiﬁcant interaction between the treatment effects of
dronedarone and the presence or absence of a history of CHF
or impaired left ventricular function (Table 1).
Patients with NYHA class II/III and left
ventricular ejection fraction ≤0.40
A total of 209 patients with stable CHF NYHA functional class II or
III in the setting of a documented LVEF ≤0.40 were enrolled in
ATHENA. Of these, 114 were assigned to receive placebo and
95 to receive dronedarone. Compared with the overall patient
population, these patients had more often coronary artery
disease, ischaemic or non-ischaemic cardiomyopathy, and were
more often having a permanent pacemaker or an implanted deﬁ-
brillator (Table 2). As summarized in Figures 1 and 2 and Table 3,
the results for all outcome measures in this patient population
were consistent with those observed in the overall population,
with fewer events in the dronedarone compared with the
placebo group. Furthermore, in this subgroup, outcomes were
not related to impairment in renal function. The HR for dronedar-
one in terms of all-cause mortality was 0.71 (95% CI ¼ 0.33–1.55)
for patients with a creatinine clearance (determined by the
Cockcroft Gault formula) of ,65 mL/min and 0.75 (95% CI ¼
0.13–4.51) for those with a clearance of ≥65 mL/min (P-value
for interaction 0.98).
Treatment-emergent adverse events (adverse events occurring
between ﬁrst study drug intake and last study drug intake +10
days) occurred in 90 of 114 placebo patients (78.9.2%) and in 65
of 95 dronedarone patients (58.4%). Serious treatment-emergent
adverse events occurred in 28.1% of placebo patients and in
16.8% of dronedarone patients. The most frequent adverse
events were infections and gastrointestinal disorders that occurred
at similar rates in the dronedarone group. The overall adverse
event proﬁle was similar to the overall patient population with
bradycardia (placebo 0.9% and dronedarone 3.2%), QT-interval
prolongation (placebo 2.6% and dronedarone 4.2%), creatinine
increase (placebo 2.6% and dronedarone 10.5%), nausea
...............................................................................................................................................................................
Table 1 Hazard ratios for the primary study endpoint for patients treated with dronedarone in relation to the presence
or absence of congestive heart failure and of impaired left ventricular ejection fraction
Patient group P (n)D ( n) Hazard ratio 95% conﬁdence interval P-value for interaction
Patients without CHF 1634 1629 0.76 0.68–0.86 0.22
Patients with CHF NYHA I/II 584 581 0.80 0.67–0.96
Patients with CHF NYHA III 109 91 0.56 0.38–0.82
Patients with LVEF ≤0.40 184 154 0.72 0.51–1.00 0.67
Patients with LVEF .0.40 2097 2109 0.77 0.69–0.85
P, placebo; D, dronedarone.
S.H. Hohnloser et al. 1718(placebo 4.4% and dronedarone 8.4%), diarrhea (placebo 9.6% and
dronedarone 14.7%), and rash (placebo 0% and dronedarone
3.2%). Fourteen patients in the placebo group (12.3%) and 18 dro-
nedarone patients (18.9%) permanently discontinued study drug
due to adverse events. The dronedarone-mediated increase in
serum creatinine was similar to the overall ATHENA population
(Figure 3).
Patients developing clinical instability
during follow-up
In ATHENA, an analysis of time to ﬁrst hospitalization for heart
failure included 132 events in the placebo group vs. 112 events
in the dronedarone group (HR ¼ 0.85, 95% CI ¼ 0.66–1.10).
3
When patients were further followed after this hospitalization,
12 patients died in the dronedarone group compared with 26 in
the placebo group.
A further analysis concerned those patients who developed an
episode of NYHA functional class IV CHF during the course of
the study. Fifty-four placebo and 42 dronedarone patients
were hospitalized while in CHF class IV (HR ¼ 0.78, 95% CI ¼
0.52–1.17). The median time from randomization to hospitaliz-
ation with NYHA class IV CHF was 227 days in the placebo arm
and 228 days in the dronedarone arm, respectively. Patients with
NYHA class IV CHF episodes were older, had more structural
heart disease (notably coronary disease and ischaemic cardiomyo-
pathy), and less lone AF compared with patients without such
episodes. When patients were further followed after in-hospital
resolution of CHF, 15 placebo patients and 10 dronedarone
patients died.
Discussion
The present exploratory analysis of ATHENA demonstrates a lack
of excess mortality or morbidity in AF patients with stable CHF
treated with dronedarone. In fact, consistent with the results of
the main trial,
3 therapy with dronedarone was associated with a
decrease in the primary study outcome in patients with NYHA
functional class III CHF at baseline. Similarly, in patients with
NYHA class II/III CHF and a LVEF ≤0.40, representing the sub-
population with systolic heart failure, event rates were not differ-
ent in the dronedarone and the placebo groups.
Figure 1 Kaplan–Meier cumulative incidence curves of time to
ﬁrst cardiovascular hospitalization or death in patients with
NYHA II/III congestive heart failure and left ventricular ejection
fraction ≤0.40 at baseline assigned to dronedarone or placebo.
.......................................................... ..............................................................
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Table 2 Selected demographics for patients in NYHA functional class II or III and with left ventricular ejection fraction
≤0.40 at baseline
NYHA II/III patients with LVEF ≤0.40 at
baseline
Remaining patients
Placebo (n 5 114) Dronedarone (n 5 95) Placebo (n 5 2167) Dronedarone (n 5 2168)
Age (years; SD) 72.0 (8.5) 71.3 (9.5) 71.7 (9.0) 71.6 (8.9)
Male gender (%) 81 (71.1%) 71 (74.7%) 1186 (54.7%) 1075 (49.6%)
Hypertension 86 (75.4%) 75 (78.9%) 1876 (86.6%) 1892 (87.3%)
Coronary heart disease 67 (58.8%) 51 (53.7%) 647 (29.9%) 600 (27.7%)
Ischaemic dilated cardiomyopathy 36 (31.6%) 35 (36.8%) 80 (3.7%) 57 (2.6%)
Non-rheumatic valvular heart disease 27 (23.7%) 28 (29.5%) 321 (14.8%) 300 (13.8%)
Non-ischaemic dilated cardiomyopathy 25 (21.9%) 18 (18.9%) 58 (2.7%) 62 (2.9%)
Pacemaker 23 (20.2%) 23 (24.2%) 215 (9.9%) 188 (8.7%)
Implanted cardioverter deﬁbrillator 22 (19.3%) 19 (20.0%) 20 (0.9%) 23 (1.1%)
Figure 2 Forrest plot for ﬁrst cardiovascular hospitalization or
death in the overall ATHENA population and patients with or
without NYHA II/III congestive heart failure and left ventricular
ejection fraction ≤0.40 at baseline.
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ﬁbrillation patients with congestive
heart failure
Most antiarrhythmic drugs are not recommended for the treat-
ment of AF in the setting of CHF and/or depressed LV function
because these patients are particularly prone to ventricular proar-
rhythmic effects and to negative inotropic action of antiarrhythmic
drugs. Current guidelines for the treatment of AF recommend only
the use of amiodarone or dofetilide in heart failure patients with
AF.
6 Whereas amiodarone is well tolerated in patients with
impaired LV function
7 and has very little proarrhythmic side
effects,
8 its use is hampered by the extracardiac side effects that
can be serious and necessitate discontinuation in a signiﬁcant pro-
portion of patients. Dofetilide, on the other hand, carries a signiﬁ-
cant proarrhythmic potential
9 which is why the drug has to be
initiated in-hospital with ECG monitoring for at least a few days.
For this reason dofetilide is not marketed in all countries. The
lack of safe and efﬁcacious pharmacological treatment options
for AF in the setting of CHF warrants careful evaluation of new
antiarrhythmic compounds.
Dronedarone for therapy of atrial
ﬁbrillation in congestive heart failure
A previous study in CHF patients using dronedarone, ANDRO-
MEDA, was terminated prematurely due to the observation of
increased mortality with dronedarone.
4 ANDROMEDA enrolled
patients with advanced CHF characterized by LVEF ≤ 0.35 and,
importantly, a recent hospitalization with new or worsening
heart failure. There were 627 patients enrolled and followed for
a median of 2 months. Thirteen excess deaths occurred on drone-
darone (HR ¼ 2.13, 95% CI ¼ 1.07–2.45, P ¼ 0.03). The excess
mortality was predominantly related to CHF (10 deaths vs. 2).
This ﬁnding contrasts the results of ATHENA where dronedarone
reduced CV mortality.
3 Speciﬁcally, ATHENA demonstrated in
4628 patients with AF at moderate to high risk for CV events
that dronedarone therapy was not associated with increased mor-
tality due to pump failure (HR ¼ 0.95, 95% CI ¼ 0.41–1.85, P ¼
0.89) or with an increase in hospitalizations for CHF (HR ¼ 0.86,
95% CI ¼ 0.67–1.10, P ¼ 0.22).
3 The present analysis extends
these observations and yields results for the population with
stable class II/III CHF in the setting of reduced LVEF. All ﬁndings
are consistent with the overall observations made in ATHENA.
Even in these high-risk subsets, there was no sign of harm associ-
ated with dronedarone therapy.
How can we understand the difference between ATHENA and
ANDROMEDA? There were 356 NYHA class III patients in
ANDROMEDA
4 compared with 200 such patients in ATHENA.
On the other hand, ATHENA included 80 times more patient
years of exposure to dronedarone than ANDROMEDA. The pres-
ence or absence of clinical stability was the primary feature that
distinguished patients enrolled in the ANDROMEDA and
ATHENA trials. Speciﬁcally, the ANDROMEDA trial was concep-
tualized primarily as a study that sought to enrol clinically unstable
patients with advanced heart disease; as such, this trial enrolled
patients who might be most likely to demonstrate a proarrhythmic
effect of dronedarone (if one existed). In contrast, the ATHENA
trial was conceptualized primarily as an efﬁcacy study and sought
to enrol patients likely to receive the drug in clinical practice, i.e.
those with recent or current AF/AFL. Although most of the
patients in the ATHENA trial had structural heart disease, they
were clinically stable. Both trials enrolled patients with low ejection
fractions or with NYHA class II or III heart failure; however, these
patients had been hospitalized for worsening heart failure in the
ANDROMEDA trial but were stable outpatients in the ATHENA
trial. The observation of a higher mortality rate in ANDROMEDA
is in line with a recent analysis of a large heart failure trial.
10
Solomon et al. elucidated the subsequent risk of death associated
with a heart failure admission (which all patients enrolled in
ANDROMEDA were required to have). They found that the mor-
tality rate was highest early after a heart failure hospitalization and
...............................................................................................................................................................................
Table 3 Outcome measures in patients in NYHA functional class II or III and with left ventricular ejection fraction
≤0.40 at baseline
Outcome measure Placebo (n 5 114) Dronedarone (n 5 95) Hazard ratio (95% CI)
Time to ﬁrst CV hospitalization or death from any cause 59 42 0.778 (0.523, 1.156)
First CV hospitalization 48 35 0.793 (0.523, 1.156)
Death from any cause 20 12 0.705 (0.344, 1.442)
First hospitalization for CHF or CV death 27 21 0.898 (0.507, 1.589)
CV, cardiovascular; CHF, congestive heart failure; CI, conﬁdence interval.
Figure 3 Changes in serum creatinine concentration relative to
baseline values during the course of the study in patients with
NYHA II/III congestive heart failure and left ventricular ejection
fraction ≤0.40 at baseline assigned to dronedarone or placebo.
S.H. Hohnloser et al. 1720declined thereafter but never reached the relative risk obtained in
patients without a heart failure hospitalization.
10 These data
suggest that patients with CHF are most vulnerable in the immedi-
ate aftermath of a hospital admission and should therefore not
receive dronedarone during this period.
Both ANDROMEDA and ATHENA observed an increase in
serum creatinine in patients receiving dronedarone. It is possible
that investigators observing a creatinine increase in ANDROMEDA
due to dronedarone inappropriately discontinued angiotensin-
converting enzyme inhibitor therapy which might have resulted
in worsening of CHF. Therefore, ATHENA investigators were
informed that a small rise in creatinine due to a speciﬁc partial inhi-
bition of tubular organic cation transporters
11 was expected with
dronedarone not indicating a decline in renal function.
Limitations of the study
Exploratory efﬁcacy analyses comprising relatively small subgroups
have inherent limitations that result from the loss of a randomiz-
ation effect. We also acknowledge the fact that the interaction ana-
lyses may be underpowered given the small patient numbers in
some of the subgroups. However, the consistency of our analyses
suggests that our ﬁndings are robust.
Clinical implications
While patients with unstable haemodynamic conditions were
excluded from ATHENA, patients with stable CHF at baseline
showed results that were consistent with those observed in the
overall ATHENA population. In patients with AF and stable CHF,
dronedarone did not increase mortality and showed a trend
towards the reduction of CV hospitalization or death. There was
no increase in CHF hospitalizations in the dronedarone arm.
According to the ANDROMEDA study, however, dronedarone
is contraindicated in patients with NYHA class IV heart failure or
unstable NYHA classes II and III heart failure with a recent decom-
pensation requiring hospitalization or referral to a specialized heart
failure clinic.
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